EVH
Evolent Health Inc
NYSE: EVH · HEALTHCARE · HEALTH INFORMATION SERVICES
$4.19
+0.48% today
Updated 2026-09-11
Market cap
$508.77M
P/E ratio
—
P/S ratio
0.24x
EPS (TTM)
$-4.39
Dividend yield
—
52W range
$2 – $10
Volume
3.1M
WallStSmart proprietary scores
52
out of 100
Grade: C
Hold
Investment rating
7.3
Growth
B+3.5
Quality
D2.0
Profitability
F4.7
Valuation
C4/9
Piotroski F-Score
Moderate
-0.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$5.77
+37.71%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
4 Strong Buy6 Buy4 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 46.90% QoQ
Risks
- Altman Z -0.57 — distress zone
- Thin margins at -24.10%
- Negative free cash flow $-23.55M
- Debt/equity 2.53x — high leverage
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.35B | $1.96B | $2.55B | $1.88B | $2.10B |
| Net income | $-19.16M | $-113.04M | $-61.62M | $-534.51M | $-28.36M |
| EPS | — | — | — | — | $-4.39 |
| Free cash flow | $-49.91M | $113.84M | $-6.13M | $4.75M | $-23.55M |
| Profit margin | -1.42% | -5.76% | -2.41% | -28.49% | -24.10% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-07-01 | WEINBERG, JONATHAN | Buy | 43,055 | — |
| 2026-07-01 | WEINBERG, JONATHAN | Sale | 2,650 | $5.74 |
| 2026-07-01 | SHAMS, AAMMAAD | Buy | 28,790 | — |
Peer comparison
Smart narrative
Evolent Health Inc trades at $4.19. Our Smart Value Score of 52/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -0.57, it sits in the distress. TTM revenue stands at $2.10B. with profit margins at -24.10%.
Frequently asked questions
What is Evolent Health Inc's stock price?
Evolent Health Inc (EVH) trades at $4.19, on a P/S of 0.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Evolent Health Inc overvalued?
Evolent Health Inc carries a Smart Value Score of 52/100 (Grade C), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Evolent Health Inc (EVH)?
The 12-month analyst consensus target is $5.77, about 37.7% above the current $4.19. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Evolent Health Inc's revenue?
Evolent Health Inc's trailing twelve-month revenue is $2.10B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Evolent Health Inc's Altman Z-Score is -0.57, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryHEALTH INFORMATION SERVICES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio0.24x
ROE-131.77%
Beta0.78
50D MA$4.77
200D MA$3.86
Shares out0.11B
Float0.09B
Short ratio—
Avg volume3.1M
Performance
1 week-3.01%
1 month-10.47%
3 months-12.71%
YTD+4.75%
1 year—
3 years—
5 years—